SecBot SecBot
SC 13G/A ·Filed Nov 5, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed11d 12h ago SEC0000315066-26-002741
Passive stake amendment
Actionable Insight • Neutral

Fidelity's passive stake is unchanged at 0.9%, indicating no material conviction signal. The filing is routine and follows the Q3 earnings release. Monitor for any future 13D conversion or significant stake changes, but no immediate action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$38.87
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.88%
T+5 · $45.82
Vs SPY
+14.59%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $38.87entry
  2. T+1 · 11d ago +15.87%α +15.56% · $45.04
  3. T+5 · 5d ago +17.88%α +14.59% · $45.82
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 970,920 shares of Edgewise Therapeutics common stock as of September 30, 2026, representing 0.9% of shares outstanding. This is a routine passive stake update filed one day after Edgewise reported Q3 results that included a large one-time gain from the sale of sevasemten. The stake is unchanged from the prior filing, and the filing carries no directional signal.

Key Financial Metrics

Stake
0.9%
Investor
FMR LLC
Investor Type
mutual fund

Key Facts

  • FMR LLC reported beneficial ownership of 970,920 shares of Edgewise Therapeutics common stock as of September 30, 2026
  • The stake represents 0.9% of shares outstanding
  • This is an amendment to a prior Schedule 13G filed August 6, 2026
  • The filing was made under Rule 13d-1(b) indicating passive investment intent
  • Filed one day after Edgewise reported Q3 2026 earnings with a $1.348 billion gain on sale of sevasemten

Financial Impact

Stake valued at approximately $36.9 million based on $4.1B market cap and 0.9% ownership

ownership_percentage

Risk Factors

  • No material risks identified from this routine passive stake filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000315066-26-002741
Document: 0000315066-26-002741-index-headers.html0000315066-26-002741
Document: 0000315066-26-002741-index.html0000315066-26-002741
Document: 0000315066-26-002741.txt0000315066-26-002741

US Market Status

Market Closed · Opens in 7h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026